Prostate Cancer Clinical Trials in San Diego

Showing 101-120 of 220 trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, Prostate+14 more

Poseida Therapeutics, Inc.40 participantsStarted Feb 2020

Duarte, California, United States • San Diego, California, United States • San Francisco, California, United States +7 more locations

COMPLETEDPhase 2< 1 mile

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02799745

The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.

Prostate Cancer

Astellas Pharma Global Development, Inc.227 participantsStarted Jun 2016

Birmingham, Alabama, United States • Homewood, Alabama, United States • Tucson, Arizona, United States +51 more locations

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Prostate Cancer Trials in Other Cities

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Stockholm3 Validation Study in a Multi-Ethnic Cohort

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Other Conditions in San Diego